Back to search results

EPX-HTG for Structural Heart Procedures

This study is looking at how a new visualization tool, EchoPixel Holographic Therapy Guidance (HTG), can improve common heart procedures. These procedures include Left Atrial Appendage Occlusion (LAAO), which helps prevent strokes in people with Atrial Fibrillation (an irregular heartbeat), and Mitral Valve Transcatheter Edge to Edge Repair (M-TEER), which fixes a leaky heart valve (Mitral Valve Regurgitation). The study wants to see if adding HTG to the usual imaging methods helps doctors place devices more accurately. You may be able to join if you are 18 or older and are already scheduled for an LAAO or M-TEER procedure at the study site using specific Philips ultrasound equipment. The main goal is to see if HTG helps achieve the best possible device position, measured 45 days after your procedure. The current status of this study is unclear.

Study design
This is an interventional study involving 20 participants. It is a prospective, single-center clinical chart review.
What's involved
The study will review your medical records, including pre-procedure CT scans, procedural ultrasound images (TEE or ICE), fluoroscopic imaging, and post-device implant images. Data will be collected on case report forms.
Compensation
Not stated in the trial record.
Follow-up
Your optimal device position will be measured 45 days after the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07705425

EPX-HTG for Structural Heart Procedures

Not Yet Recruiting
NAAges 18+InterventionalTreatment
EchoPixel, Inc.
~20 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:Left Atrial Appendage OcclusionMitral Valve Transcatheter Edge to Edge Repair

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Optimal Device Position.
Measured over 45 days post procedure.

Conditions

Atrial Fibrillation (AF)
Mitral Valve (MV) Regurgitation

Explore related trials

Atrial FibrillationMitral Valve Insufficiency

NCT07705425

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of California, Davis

    Sacramento, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Gagan D Singh, MD · PRINCIPAL_INVESTIGATOR · UC Davis Health

Who to contact

Sergio Aguirre, MSc
[email protected]
6503382559 · ext. 701
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All patients 18 and older scheduled for LAAO or M-TEER at the study site and whose procedure will use Philips CVx TEE or 3D ICE.

Exclusion

Patients whose procedures would require a GE or Siemens ultrasound system.

What this trial measures

  • Optimal Device Position.45 days post procedure.

    For both LAAO and M-TEER procedures an optimal device position will be established in pre-procedure planning. The optimal device position will be evaluated at the time of the procedure and in post-procedure imaging.